Approved Study Database

Ref. No. Scientific Title Principal investigator
2017.404 ElevatION: CRC-101: A Phase Ib study of PDR001 in combination with bevacizumab and mFOLFOX6 as first line therapy in patients with metastatic MSS colorectal cancer Prof. MA Brigette Buig Yue
馬碧如教授
2014.357 A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED WITH ERLOTINIB OR ALECTINIB IN PATIENTS WITH ADVANCED NON−SMALL CELL LUNG CANCER Prof. MA Brigette Buig Yue
2017.247 Phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer Prof. MA Brigette Buig Yue
馬碧如教授
2017.357 A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies Prof. MA Brigette Buig Yue
馬碧如教授
2016.385 A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies Prof. MA Brigette Buig Yue
馬碧如教授
2016.443 A PHASE III, OPEN LABEL, MULTICENTER, THREE-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY VS. REGORAFENIB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC COLORECTAL ADENOCARCINOMA Prof. MA Brigette Buig Yue
馬碧如
2023.455 Multi-modal Deep Learning of Multiomics Profiles, Radiology and Histopathology Images to Advance Colorectal Cancer Classification for Precision Oncology Prof. MA Brigette Buig Yue
馬碧如
2022.413 A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer Prof. MA Brigette Buig Yue
馬碧如
2020.591 AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA Prof. MA Brigette Buig Yue
馬碧如
2022.408 Clinical application of circulating tumour DNA (ctDNA) assay for monitoring treatment response in advanced gastrointestinal cancers (‘PROCURE-liquid’ program) Prof. MA Brigette Buig Yue
2023.373 A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma Prof. MA Brigette Buig Yue
2021.556 A phase 2 trial of TAS 102 in recurrent/metastatic nasopharyngeal carcinoma Prof. MA Brigette Buig Yue
馬碧如
2021.630 An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus- Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma Prof. MA Brigette Buig Yue
2020.457 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB IN COMBINATION WITH PACLITAXEL AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, UNRESECTABLE RECURRENT, OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA Prof. MA Brigette Buig Yue
馬碧如 教授
2019.327 A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies Prof. MA Brigette Buig Yue
馬碧如教授
2019.342 Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer Prof. MA Brigette Buig Yue
馬碧如教授
2020.367 A FIRST IN-HUMAN, PHASE 1/2 STUDY OF CFI-402411, HEMATOPOIETIC PROGENITOR KINASE-1 (HPK1) INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES Prof. MA Brigette Buig Yue
馬碧如教授
2018.436 A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer Prof. MA Brigette Buig Yue
馬碧如教授
2019.002 A phase I/Ib, open-label, multi-center, study of DKY709 as a single agent and in combination with PDR001 in patients with advanced solid tumors Prof. MA Brigette Buig Yue
馬碧如教授
2019.684 An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments Prof. MA Brigette Buig Yue
馬碧如教授
2020.168 A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Prof. MA Brigette Buig Yue
馬碧如
2026.235 A randomized, open label, 3-arm Phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03) Prof. MA Brigette Buig Yue
2025.386 A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012) Prof. MA Brigette Buig Yue
2025.202 A PHASE I DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY CLINICAL ACTIVITY OF RO7673396 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING RAS MUTATION(S) Prof. MA Brigette Buig Yue
2024.095 A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors Prof. MA Brigette Buig Yue
2025.375 tReatment Individualisation By EBV stratificatiON in nasopharyngeal carcinoma: an umbrella platform study (RIBBON-Umbrella) Prof. MA Brigette Buig Yue
2025.199 A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy or in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors Prof. MA Brigette Buig Yue
2024.483 A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy Prof. MA Brigette Buig Yue
2025.362 Phase I-II study of JS207 a bispecific antibody against PD1-VEGF in the treatment of recurrent/metastatic nasopharyngeal carcinoma Prof. MA Brigette Buig Yue
2024.063 NRG-HN011: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB VERSUS NIVOLUMAB AND BMS-986016 (RELATLIMAB) AS MAINTENANCE TREATMENT AFTER FIRST-LINE TREATMENT WITH PLATINUM-GEMCITABINE-NIVOLUMAB FOR PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED RECURRENT/METASTATIC NASOPHARYNGEAL CARCINOMA (REMAIN) Prof. MA Brigette Buig Yue
2024.647 A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) Prof. MA Brigette Buig Yue
2024.659 A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers Prof. MA Brigette Buig Yue
馬碧如
2017.540 A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors Prof. MA Brigette Buig Yue
馬碧如教授
2019.153 A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies Prof. MA Brigette Buig Yue
馬碧如教授
2020.054 A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors Prof. MA Brigette Buig Yue
馬碧如教授
2010.251 Uncontrolled, open-label, non-randomized, phase 1 study to investigate the pharmacokinetics, safety, tolerability, and efficacy of BAY 73-4506 in Chinese patients with advanced, refractory solid tumors Associate Professor Ma Brigette Buig-Yue
2010.473 An East Asian phase I, multicenter, open-label, dose-escalation study of oral LDE225 in patients with advanced solid tumors Associate Prof. Ma Buig Yue Brigette
2025.419 EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease Prof. MA Ching Wan
馬青雲
2025.544 A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants with Dyslipidaemia (AZURE-CHINA) Prof. MA Ching Wan
馬青雲
2010.466 SAVOR Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus A Multicenter, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes Professor Ma Ching Wan Ronald
2012.052 An evaluation on the effectiveness, acceptability and pricing of annual complication assessment for people with diabetes mellitus in the Hong Kong Community Prof Ma Ching-wan, Ronald
2011.506 Transvaginal ultrasound probe contamination by the Human Papillomavirus in the Emergency Department Dr. MA Christine Shuk Ting
2017.282 Mindfulness-based cognitive therapy for community-dwelling adults with anxiety symptoms: An exploration of efficacy and cognitive mechanism Miss MA Duan Yang
馬端陽
2012.321 An opinion Survey among frail elderly patients and their carers regarding their opinion about self-financed community care services Dr MA HON MING
2009.415 A Cohort Study on the Clinical Outcomes of Elderly Patients Admitted for Community Acquired Pneumonia (CAP) Dr. MA Hon Ming
2023.153 Mitochondrial disease related mortality - evaluation of a large international cohort Dr. MA Kam Hung
2013.407 Pharmacokinetic study of once-daily formulation of Tacrolimus (Advagraf_) in Chinese kidney transplant patients Dr Ma King Wing, Terry
2022.043 Effects of a structured Tai Chi program on improving physical activity level, exercise self-efficacy, and health outcomes among pregnant women: A randomised controlled trial Ms. MA Nan
马楠
2015.241 A Transdiagnostic Anger Management Program for Adult Psychiatric Inpatient Ms. MA Olivia
馬婉婷
2015.458 The effect of imagery and rumination on depression: a mediation and intervention study Ms. MA Olivia
馬婉婷

Page 177 of 289.